- Home
- WNS vs MYGN Comparison
WNS vs MYGN Comparison
Compare WNS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNS
- MYGN
- Stock Information
- Founded
- WNS 1996
- MYGN 1991
- Country
- WNS India
- MYGN United States
- Employees
- WNS N/A
- MYGN N/A
- Industry
- WNS Business Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- WNS Consumer Discretionary
- MYGN Health Care
- Exchange
- WNS Nasdaq
- MYGN Nasdaq
- Market Cap
- WNS 2.3B
- MYGN 2.0B
- IPO Year
- WNS N/A
- MYGN 1995
- Fundamental
- Price
- WNS $47.27
- MYGN $13.50
- Analyst Decision
- WNS Buy
- MYGN Hold
- Analyst Count
- WNS 7
- MYGN 11
- Target Price
- WNS $60.43
- MYGN $24.27
- AVG Volume (30 Days)
- WNS 473.4K
- MYGN 1.1M
- Earning Date
- WNS 01-16-2025
- MYGN 02-25-2025
- Dividend Yield
- WNS N/A
- MYGN N/A
- EPS Growth
- WNS N/A
- MYGN N/A
- EPS
- WNS 2.50
- MYGN N/A
- Revenue
- WNS $1,308,696,000.00
- MYGN $823,600,000.00
- Revenue This Year
- WNS N/A
- MYGN $13.82
- Revenue Next Year
- WNS $7.88
- MYGN $4.59
- P/E Ratio
- WNS $18.97
- MYGN N/A
- Revenue Growth
- WNS 2.07
- MYGN 12.15
- 52 Week Low
- WNS $39.85
- MYGN $12.87
- 52 Week High
- WNS $72.57
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- WNS 43.15
- MYGN 32.61
- Support Level
- WNS $45.80
- MYGN $13.04
- Resistance Level
- WNS $47.91
- MYGN $13.77
- Average True Range (ATR)
- WNS 1.57
- MYGN 0.60
- MACD
- WNS 0.07
- MYGN 0.14
- Stochastic Oscillator
- WNS 53.46
- MYGN 24.51
About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)
WNS (Holdings) Ltd is a Global provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), and South Africa.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.